DZ2880A1 - Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. - Google Patents

Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Info

Publication number: DZ2880A1
Authority: DZ; Algeria
Prior art keywords: alkynyl; derivatives; preparation; pharmaceutical compositions; compositions containing
Prior art date: 1998-08-27

Application number

DZ990180A

Other languages

English (en)

French (fr)

Inventor

La Susan Deborah Crega

Joseph Peter Lyssikatos

Original Assignee

Pfizer Prod Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-08-27

Filing date

1999-08-25

Publication date

2003-12-15

1999-08-25 Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DZ2880A1 publication Critical patent/DZ2880A1/xx

Links

239000008194 pharmaceutical composition Substances 0.000 title 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DZ990180A 1998-08-27 1999-08-25 Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant. DZ2880A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US9814598P	1998-08-27	1998-08-27

Publications (1)

Publication Number	Publication Date
DZ2880A1 true DZ2880A1 (fr)	2003-12-15

Family

ID=22267481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ990180A DZ2880A1 (fr)	1998-08-27	1999-08-25	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.

Country Status (40)

Country	Link
US (3)	US6150377A (cs)
EP (1)	EP1107963B1 (cs)
JP (1)	JP3495706B2 (cs)
KR (1)	KR20010072991A (cs)
CN (1)	CN1314904A (cs)
AP (1)	AP2001002079A0 (cs)
AT (1)	ATE321037T1 (cs)
AU (1)	AU4925499A (cs)
BG (1)	BG105365A (cs)
BR (1)	BRPI9913138B8 (cs)
CA (2)	CA2341690C (cs)
CO (1)	CO5130017A1 (cs)
CZ (1)	CZ2001660A3 (cs)
DE (1)	DE69930518T2 (cs)
DZ (1)	DZ2880A1 (cs)
EA (1)	EA200100135A1 (cs)
EE (1)	EE200100118A (cs)
ES (1)	ES2259237T3 (cs)
GE (1)	GEP20033001B (cs)
GT (1)	GT199900140A (cs)
HK (1)	HK1039123A1 (cs)
HR (1)	HRP20010142A2 (cs)
HU (1)	HUP0103228A3 (cs)
ID (1)	ID27562A (cs)
IL (1)	IL141239A0 (cs)
IS (1)	IS5818A (cs)
MA (1)	MA26680A1 (cs)
NO (1)	NO20010964L (cs)
NZ (1)	NZ509372A (cs)
OA (1)	OA11645A (cs)
PA (1)	PA8480101A1 (cs)
PE (1)	PE20000986A1 (cs)
PL (1)	PL346426A1 (cs)
SK (1)	SK2442001A3 (cs)
SV (1)	SV1999000141A (cs)
TN (1)	TNSN99162A1 (cs)
TR (1)	TR200101343T2 (cs)
UY (1)	UY25682A1 (cs)
WO (1)	WO2000012499A1 (cs)
ZA (1)	ZA200101173B (cs)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030114503A1 (en) *	1997-06-16	2003-06-19	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer
HRP20000904A2 (en) *	1998-07-06	2001-12-31	Janssen Pharmaceutica Nv	Farnesyl protein transferase inhibitors for treating arthropathies
TR200101343T2 (tr) *	1998-08-27	2001-09-21	Pfizer Products Inc.	Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri
DE69923849T2 (de) *	1998-08-27	2006-01-12	Pfizer Products Inc., Groton	Quinolin-2-on-derivate verwendbar als antikrebsmittel
SK11002001A3 (sk)	1999-02-11	2002-05-09	Pfizer Products Inc.	Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky
HN2000000266A (es)	2000-01-21	2001-05-21	Pfizer Prod Inc	Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
ATE375794T1 (de)	2000-02-24	2007-11-15	Janssen Pharmaceutica Nv	Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
JO2361B1 (en)	2000-06-22	2006-12-12	جانسين فارماسيوتيكا ان. في	Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl
WO2002024686A2 (en) *	2000-09-25	2002-03-28	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives
US7067531B2 (en)	2000-09-25	2006-06-27	Angibaud Patrick Rene	Farnesyl transferase inhibiting 6-heterocyclylmethyl quinolinone derivatives
JP4974437B2 (ja)	2000-09-25	2012-07-11	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する６−［（置換フェニル）メチル］−キノリンおよびキナゾリン誘導体
DE60118225T2 (de)	2000-09-25	2007-05-03	Janssen Pharmaceutica N.V.	Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren
AU2002214056A1 (en)	2000-11-21	2002-06-03	Janssen Pharmaceutica N.V.	Farnesyl transferase inhibiting benzoheterocyclic derivatives
CA2632091C (en) *	2000-12-19	2011-03-22	Pfizer Products Inc.	Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production
JP4351445B2 (ja) *	2000-12-27	2009-10-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	ファルネシルトランスフェラーゼを阻害する４−置換−キノリンおよびキナゾリン誘導体
AU2002236813A1 (en) *	2001-01-22	2002-07-30	Schering Corporation	Treatment of malaria with farnesyl protein transferase inhibitors
BRPI0208075B8 (pt) *	2001-03-12	2021-05-25	Janssen Pharmaceutica Nv	processo para a preparação de compostos de imidazol
US20020151563A1 (en) *	2001-03-29	2002-10-17	Pfizer Inc.	Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
AU2002257114A1 (en) *	2001-04-06	2002-10-21	Schering Corporation	Treatment of malaria with farsenyl protein transferase inhibitors
WO2002098425A1 (en) *	2001-06-04	2002-12-12	Cytovia, Inc.	Substituted 4-aryl-3-(3-aryl-1-oxo-2-propenyl)-2(1h)-quinolinones and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP1408971A4 (en)	2001-06-21	2006-01-25	Ariad Pharma Inc	NEW QUINOLINES AND THEIR USES
US6740757B2 (en) *	2001-08-29	2004-05-25	Pfizer Inc	Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
EP1458720B1 (en)	2001-12-19	2009-03-18	Janssen Pharmaceutica N.V.	1,8-annelated quinoline derivatives substituted with carbon-linked triazoles as farnesyl transferase inhibitors
EP1490065B1 (en)	2002-03-22	2007-06-13	Janssen Pharmaceutica N.V.	Benzylimidazolyl substituted 2-quinolinone and quinazolinone derivatives for use as farnesyl transferase inhibitors
DE60307616T2 (de)	2002-04-15	2007-10-04	Janssen Pharmaceutica N.V.	Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
WO2004056806A1 (en) *	2002-12-19	2004-07-08	Pfizer Inc.	2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases
JP4691041B2 (ja)	2003-11-20	2011-06-01	チルドレンズホスピタルメディカルセンター	Ｇｔｐアーゼ阻害剤および使用方法
US20050272722A1 (en) *	2004-03-18	2005-12-08	The Brigham And Women's Hospital, Inc.	Methods for the treatment of synucleinopathies
CA2561516A1 (en) *	2004-03-30	2005-10-13	Pfizer Products Inc.	Combinations of signal transduction inhibitors
BR122020017756B1 (pt) *	2004-08-26	2022-02-15	Pfizer Inc	Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
BRPI0514687A (pt) *	2004-08-26	2008-06-17	Pfizer	compostos amino heteroarila como inibidores de proteìna tirosina cinase
ME01309B (me) *	2004-08-26	2013-12-20	Pfizer	Pirazolom supstituirani heteroarilni spojevi kao inhibitori proteinskih kinaza
ES2403060T3 (es)	2004-11-05	2013-05-13	Janssen Pharmaceutica Nv	Uso terapéutico de inhibidores de la farnesiltransferasa y métodos de control de la eficacia de los mismos.
US20060107555A1 (en) *	2004-11-09	2006-05-25	Curtis Marc D	Universal snow plow adapter
US20060281788A1 (en)	2005-06-10	2006-12-14	Baumann Christian A	Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
WO2007016539A2 (en)	2005-07-29	2007-02-08	Children's Hospital Medical Center	Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase
CA2621371C (en)	2005-09-07	2018-05-15	Amgen Fremont Inc.	Human monoclonal antibodies to activin receptor-like kinase-1
AU2006292278B2 (en)	2005-09-20	2012-03-08	Osi Pharmaceuticals, Inc.	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP1968591A4 (en)	2005-12-23	2010-02-17	Link Medicine Corp	TREATMENT OF SYNUCLEINOPATHIES
TW200812615A (en)	2006-03-22	2008-03-16	Hoffmann La Roche	Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
BRPI0710548B8 (pt)	2006-04-20	2021-05-25	Janssen Pharmaceutica Nv	inibidores de c-fms cinase, composição farmacêutica e forma de dosagem farmacêutica
NZ572073A (en)	2006-04-20	2011-09-30	Janssen Pharmaceutica Nv	Heterocyclic compounds as inhibitors of c-fms kinase
US8697716B2 (en)	2006-04-20	2014-04-15	Janssen Pharmaceutica Nv	Method of inhibiting C-KIT kinase
EA200802058A1 (ru)	2006-05-09	2009-06-30	Пфайзер Продактс Инк.	Производные циклоалкиламинокислот и их фармацевтические композиции
DK2056874T3 (da)	2006-08-21	2012-10-15	Hoffmann La Roche	Tumorterapi med et anti-vegf-antistof
WO2008112525A2 (en) *	2007-03-09	2008-09-18	Link Medicine Corporation	Treatment of lysosomal storage diseases
JO3240B1 (ar)	2007-10-17	2018-03-08	Janssen Pharmaceutica Nv	c-fms مثبطات كيناز
WO2009151683A2 (en)	2008-03-12	2009-12-17	Link Medicine Corporation	Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
DE102008022221A1 (de) *	2008-05-06	2009-11-12	Universität des Saarlandes	Inhibitoren der humanen Aldosteronsynthase CYP11B2
US20110060005A1 (en) *	2008-11-13	2011-03-10	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
JP2012508768A (ja)	2008-11-13	2012-04-12	リンク・メディスン・コーポレーション	アザキノリノン誘導体及びその使用
US20100331363A1 (en) *	2008-11-13	2010-12-30	Link Medicine Corporation	Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
US20110171124A1 (en)	2009-02-26	2011-07-14	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the EMT status of tumor cells in vivo
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en)	2009-02-27	2012-01-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
CA2783665A1 (en)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2783656A1 (en)	2010-03-03	2011-09-09	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
US20120214830A1 (en)	2011-02-22	2012-08-23	OSI Pharmaceuticals, LLC	Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
EP2702173A1 (en)	2011-04-25	2014-03-05	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
US9980942B2 (en)	2012-05-02	2018-05-29	Children's Hospital Medical Center	Rejuvenation of precursor cells
JP6290884B2 (ja)	2012-08-07	2018-03-07	ヤンセンファーマシューティカエヌ．ベー．	ｃ−ＦＭＳキナーゼ阻害剤の調製プロセス
IN2015DN00659A (cs)	2012-08-07	2015-06-26	Janssen Pharmaceutica Nv
US9180185B2 (en)	2013-01-11	2015-11-10	Hoffman-La Roche Inc.	Combination therapy of anti-HER3 antibodies
US10028503B2 (en)	2014-06-18	2018-07-24	Children's Hospital Medical Center	Platelet storage methods and compositions for same
HUE044698T2 (hu)	2015-08-17	2019-11-28	Kura Oncology Inc	Kezelési módszer rákos páciensek kezelésére farnezil-transzferáz inhibitorokkal
CN108601752A (zh)	2015-12-03	2018-09-28	安吉奥斯医药品有限公司	用于治疗mtap缺失型癌症的mat2a抑制剂
WO2017184968A1 (en)	2016-04-22	2017-10-26	Kura Oncology, Inc.	Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
JP2019534290A (ja)	2016-11-03	2019-11-28	クラオンコロジー，インコーポレイテッド	癌の治療方法において使用するためのファルネシルトランスフェラーゼ阻害剤
JP7341060B2 (ja)	2017-02-10	2023-09-08	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	Ｍａｐｋ経路の活性化に関連付けられる癌の処置のための方法及び医薬組成物
EP4119142A1 (en)	2017-02-21	2023-01-18	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
US9956215B1 (en)	2017-02-21	2018-05-01	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
MY200746A (en)	2017-08-07	2024-01-13	Kura Oncology Inc	Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en)	2017-08-07	2020-10-20	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2019113269A1 (en)	2017-12-08	2019-06-13	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
TW202031259A (zh)	2018-11-01	2020-09-01	美商庫拉腫瘤技術股份有限公司	以法尼基轉移酶(farnesyltransferase)抑制劑治療癌症之方法
TW202038953A (zh)	2018-12-21	2020-11-01	美商庫拉腫瘤技術股份有限公司	鱗狀細胞癌之治療
WO2020180663A1 (en)	2019-03-01	2020-09-10	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
WO2020190604A1 (en)	2019-03-15	2020-09-24	Kura Oncology, Inc.	Methods of treating cancer patients with farnesyltransferase inhibitors
AU2020254492A1 (en)	2019-03-29	2021-11-11	Kura Oncology, Inc.	Methods of treating Squamous Cell Carcinomas with farnesyltransferase inhibitors
WO2020205387A1 (en)	2019-04-01	2020-10-08	Kura Oncology, Inc.	Methods of treating cancer with farnesyltransferase inhibitors
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
WO2020223583A1 (en)	2019-05-02	2020-11-05	Kura Oncology, Inc.	Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CA3151110A1 (en)	2019-08-16	2021-02-25	Children's Hospital Medical Center	Methods of treating a subject with a cdc42-specific inhibitor
WO2021155006A1 (en)	2020-01-31	2021-08-05	Les Laboratoires Servier Sas	Inhibitors of cyclin-dependent kinases and uses thereof
WO2024061357A1 (zh) *	2022-09-22	2024-03-28	南开大学	三尖杉酯碱类衍生物及其药物组合物、制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5747498A (en) *	1996-05-28	1998-05-05	Pfizer Inc.	Alkynyl and azido-substituted 4-anilinoquinazolines
TW349948B (en) *	1995-10-31	1999-01-11	Janssen Pharmaceutica Nv	Farnesyl transferase inhibiting 2-quinolone derivatives
DE69620445T2 (de) *	1995-12-08	2002-12-12	Janssen Pharmaceutica N.V., Beerse	(imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
TR200101343T2 (tr) *	1998-08-27	2001-09-21	Pfizer Products Inc.	Kansere karşı kullanılan maddeler olarak alkinil-ikame edilmiş kinolin-2-on türevleri

1999
- 1999-08-06 TR TR2001/01343T patent/TR200101343T2/xx unknown
- 1999-08-06 HR HR20010142A patent/HRP20010142A2/hr not_active Application Discontinuation
- 1999-08-06 DE DE69930518T patent/DE69930518T2/de not_active Expired - Lifetime
- 1999-08-06 AP APAP/P/2001/002079A patent/AP2001002079A0/en unknown
- 1999-08-06 KR KR1020017002442A patent/KR20010072991A/ko not_active Ceased
- 1999-08-06 CA CA002341690A patent/CA2341690C/en not_active Expired - Fee Related
- 1999-08-06 NZ NZ509372A patent/NZ509372A/en unknown
- 1999-08-06 AT AT99933084T patent/ATE321037T1/de not_active IP Right Cessation
- 1999-08-06 CZ CZ2001660A patent/CZ2001660A3/cs unknown
- 1999-08-06 ID IDW20010457A patent/ID27562A/id unknown
- 1999-08-06 EE EEP200100118A patent/EE200100118A/xx unknown
- 1999-08-06 SK SK244-2001A patent/SK2442001A3/sk unknown
- 1999-08-06 BR BRPI9913138A patent/BRPI9913138B8/pt not_active IP Right Cessation
- 1999-08-06 JP JP2000567527A patent/JP3495706B2/ja not_active Expired - Fee Related
- 1999-08-06 GE GEAP19995770A patent/GEP20033001B/en unknown
- 1999-08-06 WO PCT/IB1999/001398 patent/WO2000012499A1/en not_active Ceased
- 1999-08-06 HK HK02100579.7A patent/HK1039123A1/zh unknown
- 1999-08-06 EA EA200100135A patent/EA200100135A1/ru unknown
- 1999-08-06 CA CA002578326A patent/CA2578326C/en not_active Expired - Fee Related
- 1999-08-06 OA OA1200100051A patent/OA11645A/en unknown
- 1999-08-06 CN CN99810204A patent/CN1314904A/zh active Pending
- 1999-08-06 IL IL14123999A patent/IL141239A0/xx unknown
- 1999-08-06 EP EP99933084A patent/EP1107963B1/en not_active Expired - Lifetime
- 1999-08-06 ES ES99933084T patent/ES2259237T3/es not_active Expired - Lifetime
- 1999-08-06 HU HU0103228A patent/HUP0103228A3/hu unknown
- 1999-08-06 PL PL99346426A patent/PL346426A1/xx not_active Application Discontinuation
- 1999-08-06 AU AU49254/99A patent/AU4925499A/en not_active Abandoned
- 1999-08-10 PA PA19998480101A patent/PA8480101A1/es unknown
- 1999-08-24 GT GT199900140A patent/GT199900140A/es unknown
- 1999-08-25 MA MA25743A patent/MA26680A1/fr unknown
- 1999-08-25 TN TNTNSN99162A patent/TNSN99162A1/fr unknown
- 1999-08-25 DZ DZ990180A patent/DZ2880A1/xx active
- 1999-08-26 PE PE1999000862A patent/PE20000986A1/es not_active Application Discontinuation
- 1999-08-26 US US09/383,755 patent/US6150377A/en not_active Expired - Lifetime
- 1999-08-27 SV SV1999000141A patent/SV1999000141A/es not_active Application Discontinuation
- 1999-08-27 UY UY25682A patent/UY25682A1/es unknown
- 1999-08-27 CO CO99054519A patent/CO5130017A1/es unknown
2000
- 2000-07-27 US US09/628,039 patent/US6294552B1/en not_active Expired - Lifetime
2001
- 2001-01-19 IS IS5818A patent/IS5818A/is unknown
- 2001-02-12 ZA ZA200101173A patent/ZA200101173B/en unknown
- 2001-02-26 NO NO20010964A patent/NO20010964L/no not_active Application Discontinuation
- 2001-03-20 BG BG105365A patent/BG105365A/xx unknown
- 2001-07-06 US US09/900,401 patent/US6579887B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GT199900140A (es)	2001-02-14
IS5818A (is)	2001-01-19
IL141239A0 (en)	2002-03-10
JP3495706B2 (ja)	2004-02-09
TR200101343T2 (tr)	2001-09-21
EE200100118A (et)	2002-06-17
WO2000012499A1 (en)	2000-03-09
CA2341690C (en)	2007-04-17
DE69930518T2 (de)	2006-09-21
ZA200101173B (en)	2002-04-12
ID27562A (id)	2001-04-12
HUP0103228A3 (en)	2003-01-28
CA2578326C (en)	2009-11-24
GEP20033001B (en)	2003-06-25
CA2341690A1 (en)	2000-03-09
PA8480101A1 (es)	2003-06-30
CO5130017A1 (es)	2002-02-27
ATE321037T1 (de)	2006-04-15
NZ509372A (en)	2003-08-29
AU4925499A (en)	2000-03-21
EP1107963A1 (en)	2001-06-20
US6579887B2 (en)	2003-06-17
HUP0103228A2 (hu)	2002-02-28
CA2578326A1 (en)	2000-03-09
KR20010072991A (ko)	2001-07-31
SK2442001A3 (en)	2002-10-08
HK1039123A1 (zh)	2002-04-12
BG105365A (en)	2001-11-30
HRP20010142A2 (en)	2002-02-28
US6294552B1 (en)	2001-09-25
MA26680A1 (fr)	2004-12-20
DE69930518D1 (de)	2006-05-11
UY25682A1 (es)	2000-03-31
AP2001002079A0 (en)	2001-03-31
JP2002523504A (ja)	2002-07-30
ES2259237T3 (es)	2006-09-16
PL346426A1 (en)	2002-02-11
US20020128287A1 (en)	2002-09-12
EP1107963B1 (en)	2006-03-22
PE20000986A1 (es)	2000-09-30
EA200100135A1 (ru)	2001-08-27
TNSN99162A1 (fr)	2005-11-10
CN1314904A (zh)	2001-09-26
NO20010964D0 (no)	2001-02-26
US6150377A (en)	2000-11-21
CZ2001660A3 (cs)	2002-05-15
BR9913138B1 (pt)	2013-11-05
OA11645A (en)	2004-11-16
SV1999000141A (es)	2000-07-06
NO20010964L (no)	2001-04-26
BR9913138A (pt)	2001-05-08
BRPI9913138B8 (pt)	2016-05-17

Publication	Publication Date	Title
DZ2880A1 (fr)	2003-12-15	Dérivés de quinoléine-2-one à substituant alcynylenouveaux procédé pour leur préparation et composi tions pharmaceutiques les contenant.
DZ2197A1 (fr)	2002-12-02	Dérivés de 6-phénylpyridyl-2-amine, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2300A1 (fr)	2002-12-25	Dérivés 6,5-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2299A1 (fr)	2002-12-25	Dérivés 6,6-hétérobicycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3009A1 (fr)	2004-03-27	Dérivés de quinoléine-2-one à substituant hétéroaryle nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2891A1 (fr)	2003-12-15	Dérivés de tétrahydroquinoléines substués nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1889A1 (fr)	2002-02-17	Dérivés de quinoléine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ1957A1 (fr)	2002-02-17	Dérivés de pipéridine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2963A1 (fr)	2004-03-15	Dérivés de bicycliques substituées nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
MA26659A1 (fr)	2004-12-20	Dérivés de benzimidazole nouveaux, compositions pharmaceutiques les contenant et procédé pour leur préparation.
DZ2634A1 (fr)	2003-03-08	Dérivés de pleuromutiline nouveaux procédé pour leur préparation et compositions pharmaceutiques lescontenant.
DZ3042A1 (fr)	2004-03-27	Dérivés d'isothiazole nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2890A1 (fr)	2003-12-15	4-Carboxamino-2-substitué-1,2,3,4-tétrahydroquinoléines, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2773A1 (fr)	2003-12-01	Pyrazolopyrimidinones nouvelles procédé pour leur préparation et compositions pharmaceutiques les contenant.
FR2708608B1 (fr)	1995-10-27	Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant.
DZ2407A1 (fr)	2003-01-04	Dérivés de sulfonylurée procédé pour leur préparation et compositions pharmaceutiques les contenant
CY2537B1 (fr)	2006-06-28	Composés hétérocycliques substitués, procédé pour leur préparation et compositions pharmaceutiques les contenant
FR2708606B1 (fr)	1995-10-27	Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
DZ2777A1 (fr)	2003-12-01	Dérivés de quinazolinamines nouveaux procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ3045A1 (fr)	2004-03-27	Dérivés de i 3-méthyl-érythromycine nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
DZ2198A1 (fr)	2002-12-02	Dérivés de lactames, procédé pour leur préparationet compositions pharmaceutiques les contenant.
DZ2188A1 (fr)	2002-12-02	Dérivés de quinoxalinedone, procédés et intermédiaires pour leur préparation et compositions pharmaceutiques les contenant.
DZ2128A1 (fr)	2002-10-26	Composés nouveaux, procédé pour leur préparation et compositions pharmaceutiques les contenant.
CH689805A8 (fr)	2000-02-29	Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
DZ2866A1 (fr)	2003-12-01	1-Aryl-3-arylméthyl-1,8-naphtyridine-4-(1H)-ones nouvelles, procédé pour leur préparation et compositions pharmaceutiques les contenant.